Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005
Alachua Government Services, Inc.
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- COMPLETED
- phase
- PHASE2, PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 1400
- sponsor
- Alachua Government Services, Inc.
- conditions
- Influenza
- interventions
- BIOLOGICAL: Vero Cell-derived Influenza Vaccine; BIOLOGICAL: Egg cell-derived Influenza Vaccine
- start date
- 2004-11-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT00161811
- Published
- Sep 13, 2005
- Updated
- Oct 9, 2015
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT00161811
- Categories
- Influenza
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials